Deena Kuruvilla, AHS 2021: External Trigeminal Nerve Stimulator as a Non-pharmacological Option for the Prevention and Acute Treatment of Migraine
touchNEUROLOGY had the pleasure to meet with Deena Kuruvilla (Westport Headache Institute, Westport, CT, USA) to discuss the Cefaly (External Trigeminal Nerve Stimulator) device as a non-pharmacological option for the prevention and acute treatment of migraine.
The abstract ‘A Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM)’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- Why is there a need for a non-pharmacological option for the prevention and acute treatment of migraine? (0:20)
- Could you tell us a little about the Cefaly device and the rationale for its use in this indication? (1:02)
- What clinical evidence supports the use of the Cefaly device? (1:48)
Disclosures: Deena Kuruvilla is a medical advisor for Cefaly.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS 2021 (Virtual).
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!